{"schema_version":"1","generated_at":"2026-10-28T00:37:15.434Z","data_as_of":null,"url":"https://www.findmykol.com/kol/anastasios-dimou","json_url":"https://www.findmykol.com/kol/anastasios-dimou/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"anastasios-dimou","name":"Anastasios Dimou","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Mayo Clinic","institution_url":"https://www.findmykol.com/institution/mayo-clinic","city":"Rochester","state":"MN","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1265729834","orcid":"0000-0002-3950-3305","openalex":"A5073550585"},"summary":"Anastasios Dimou is an Oncology physician affiliated with Mayo Clinic. OpenAlex indexes 148 publications with 1,534 citations (h-index 20); ClinicalTrials.gov lists 3 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":148,"cited_by_count":1534,"h_index":20,"latest_activity_year":2025,"source":"works"},"trials":{"count":3,"shown":3,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT05393713","title":"Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study","phase":"PHASE1","status":"TERMINATED","role":"Overall official","sponsor":"Mayo Clinic","source_url":"https://clinicaltrials.gov/study/NCT05393713","trial_url":"https://www.findmykol.com/trial/NCT05393713"},{"nct":"NCT04967196","title":"Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma","phase":"PHASE1","status":"TERMINATED","role":"Overall official","sponsor":"Mayo Clinic","source_url":"https://clinicaltrials.gov/study/NCT04967196","trial_url":"https://www.findmykol.com/trial/NCT04967196"},{"nct":"NCT04607954","title":"Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"Mayo Clinic","source_url":"https://clinicaltrials.gov/study/NCT04607954","trial_url":"https://www.findmykol.com/trial/NCT04607954"}],"source":"trials"},"payments":{"company_count":6,"program_years":{"first":2021,"last":null},"rows_total":6,"shown":3,"withheld":3,"rows":[{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":68.49,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1265729834"},{"payer":"Rigel Pharmaceuticals, Inc.","program_year":2024,"amount_usd":3273.48,"payment_count":5,"source_url":"https://openpaymentsdata.cms.gov/search?query=1265729834"},{"payer":"ChromaCode, Inc","program_year":2023,"amount_usd":1500,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1265729834"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1265729834","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Pooled safety analysis and management of sotorasib-related adverse events in <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer","year":2025,"journal":"The Oncologist","source_url":"https://doi.org/10.1093/oncolo/oyae356","status":"verified"},{"title":"Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial","year":2025,"journal":"Journal for ImmunoTherapy of Cancer","source_url":"https://doi.org/10.1136/jitc-2025-011706","status":"verified"},{"title":"NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma","year":2025,"journal":"European Journal of Cancer","source_url":"https://doi.org/10.1016/j.ejca.2025.115688","status":"verified"},{"title":"Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database","year":2024,"journal":"Journal of Thoracic Oncology","source_url":"https://doi.org/10.1016/j.jtho.2024.07.009","status":"verified"},{"title":"Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial","year":2024,"journal":"Nature Communications","source_url":"https://doi.org/10.1038/s41467-024-45798-8","status":"verified"}],"source":"works"},"contact":{"address_1":"200 1ST ST SW","city":"Rochester","state":"MN","zip":"55905","phone":"507-284-2511","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1265729834","source":"identity"},"similar":[{"name":"S Rajkumar","slug":"s-rajkumar","institution":"Mayo Clinic","specialty":"Hematology","url":"https://www.findmykol.com/kol/s-rajkumar","json_url":"https://www.findmykol.com/kol/s-rajkumar/profile.json"},{"name":"Bradley Boeve","slug":"bradley-boeve","institution":"Mayo Clinic","specialty":"Neurology","url":"https://www.findmykol.com/kol/bradley-boeve","json_url":"https://www.findmykol.com/kol/bradley-boeve/profile.json"},{"name":"Victor Montori","slug":"victor-montori","institution":"Mayo Clinic","specialty":"Endocrinology, Diabetes & Metabolism","url":"https://www.findmykol.com/kol/victor-montori","json_url":"https://www.findmykol.com/kol/victor-montori/profile.json"},{"name":"Ayalew Tefferi","slug":"ayalew-tefferi","institution":"Mayo Clinic","specialty":"Hematology","url":"https://www.findmykol.com/kol/ayalew-tefferi","json_url":"https://www.findmykol.com/kol/ayalew-tefferi/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":3,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2020-08-13","provider_certified":"2020-08-13","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}